Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 84 recommandations pour 64 médicaments et 21 équivalents thérapeutiques
Les médicaments retirés et les demandes rejetées ne sont pas indiqués. Les afficher.
Biological
  1. BCG vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Japanese encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Adalimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  4. Ansuvimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  5. Anti-D immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Maternal care for red cell antibodies Rh incompatibility reaction
  6. Anti-rabies immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  7. Anti-rabies virus monoclonal antibodies Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  8. Anti-tetanus immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  9. Antivenom immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  10. Asparaginase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  11. Atoltivimab + maftivimab + odesivimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  12. Bevacizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  13. Certolizumab pegol Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  14. Cholera vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  15. Coagulation factor IX Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  16. Coagulation factor IX complex Informations générales
    Section
    Blood coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX pour Haemophilia B
  17. Coagulation factor VIII Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  19. Cryoprecipitate (pathogen-reduced) Informations générales
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Haemophilia A Coagulation defects, purpura or other haemorrhagic or related conditions Von Willebrand disease Obstetric haemorrhage
  20. Dalteparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  21. Darbepoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  22. Dengue vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  23. Diphtheria antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  24. Diphtheria vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  25. Enoxaparin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  26. Epoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  27. Epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  28. Epoetin theta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  29. Equine rabies immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  30. Erythropoiesis-stimulating agents Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  31. Etanercept Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  32. Filgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  33. Fresh-frozen plasma Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  34. Golimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  35. Haemophilus influenzae type b vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  36. Hepatitis A vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  37. Hepatitis B vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  38. Human papilloma virus (HPV) vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  39. Infliximab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  40. Influenza vaccine (seasonal) Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  41. Insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  42. Insulin degludec Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  43. Insulin detemir Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  44. Insulin glargine Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  45. Intermediate-acting insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  46. Long-acting insulin analogues Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  47. Measles vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  48. Meningococcal meningitis vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  49. Methoxy polyethylene glycol-epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  50. Mumps vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  51. Nadroparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  52. Nivolumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  53. Normal immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis
  54. Pegaspargase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  55. Pegfilgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  56. Pembrolizumab Informations générales
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab pour Melanoma of skin
  57. Pertussis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  58. Platelets Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  59. Pneumococcal vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  60. Poliomyelitis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  61. Rabies vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  62. Red blood cells Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  63. Rituximab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  64. Rotavirus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  65. Rubella vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  66. Surfactant Informations générales
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  67. Tetanus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  68. Tick-borne encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  69. Trastuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  70. Typhoid vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  71. Varicella vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  72. Whole blood Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  73. Yellow fever vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases